Buy or Sell: PBLA Stock Forecast 2023, 2024, 2025, 2030 to 2050

Today, we’re going on a journey to explore the performance of Panbela Therapeutics Inc (NASDAQ: PBLA) in recent times and provide you with a well-researched PBLA Stock Forecast for growth prospects. By the end of our journey, you will have a better understanding of the PBLA Stock Forecast for the years 2023 to 2050.

Additionally, we will also take into analysis PBLA Stock Recommendations from various brokerage firms, including target high price, target low price, mean recommendation, and key recommendation at the end of the article.

Overview of PBLA

NamePanbela Therapeutics, Inc.
CEODr. Jennifer
K. Simpson CRNP,
M.S.N., Ph.D.
Headquarters712 Vista Blvd #305, Waconia, Minnesota, 55387, United States
ServicesDevelopment of therapeutics for the treatment of patients with cancer
CountryUnited States

Keep an eye on PBLA’s share price today with real-time updates, and examine its performance on the stock market through comprehensive charts that display the fluctuations in PBLA’s stock price.

PBLA Stock Price Live

About PBLA Company

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, is at the forefront of developing innovative therapeutics for critical medical needs that are yet to be met. The company’s primary focus is on creating treatments for patients suffering from pancreatic cancer, a field where advancements are urgently needed.

Innovative Approach in Therapeutics– Panbela’s strategy revolves around Polyamine Metabolic Inhibitors (PMIs). These PMIs are designed to regulate polyamines, which are crucial in normal biology and often altered in various diseases. By targeting these polyamines, Panbela aims to reset the dysregulated biology in diseases, especially in oncology and rare disorders. This approach signifies a multi-targeted strategy to address complex diseases with high unmet medical needs.

Clinical Trials and Research– Panbela is actively engaged in various stages of clinical trials, ranging from pre-clinical to Phase III registration programs. The company’s late-stage programs are particularly focused on orphan oncology, including pancreatic cancer and familial adenomatous polyposis (FAP).

Notably, the ASPIRE trial, a significant global study for metastatic pancreatic ductal adenocarcinoma, is underway, targeting 60-80 sites worldwide. Additionally, a Phase III Registration trial for FAP is anticipated to commence in the first half of 2023.

Recent Achievements and Updates– Panbela has made significant strides in its field. The company announced the US WorldMeds NDA approval for Eflornithine (DFMO) in treating pediatric neuroblastoma.

Furthermore, Panbela has been involved in evaluating the viability of myeloma cell lines following the administration of SBP-101 and DFMO polyamine inhibitors. These achievements underscore the company’s commitment to advancing cancer treatment.

PBLA Stock Price History

PBLA Stock Forecast 2023 to 2050

We will analyze the performance of the company’s shares in recent times and provide you with a well-researched PBLA Stock Forecast for 2023, 2025 to 2050, based on our Research knowledge and forecasting. let’s see first The fundamental analysis of PBLA Stock focuses on key factors to better understand the company’s valuation.


Capital Stock Issuance: The company has shown a consistent ability to raise capital through the issuance of stock, as indicated by the figures in the cash flow statement (e.g., 28,401 in TTM).

Financing Cash Flow: Positive financing cash flow, such as 26,742 in TTM, suggests the company is effective in securing funds through financing activities.


Consistent Net Losses: The income statement reveals persistent net losses over the years, with the net income for common stockholders being negative (e.g., -23,524 in TTM).

High Operating Expenses: Operating expenses have been consistently high relative to revenue, leading to negative operating income.

Negative Working Capital: The working capital being negative (-6,056 in 2022) indicates potential short-term financial instability.

Decreasing Total Assets: A reduction in total assets from 12,872 in 2021 to 4,978 in 2022 suggests a shrinking asset base.


Debt Management: The company has minimal debt obligations, offering an opportunity to leverage financing for growth without overburdening with high-interest expenses.

Investing Activities: There’s room for strategic investing activities, as indicated by the modest figures in the investing cash flow section.


Equity Erosion: Negative total equity (e.g., -8,049 in 2022) indicates a severe erosion of shareholder value.

Sustainability Concerns: The continuous negative free cash flow (e.g., -27,172 in TTM) raises concerns about the long-term sustainability of the business.

PBLA Stock Forecast 2023

For 2023, we expect PBLA’s stock price to remain volatile, with a minimum target of $0.50 USD and a maximum target of $2.50 USD. The company’s financial performance will largely depend on its ability to secure additional funding to support its operations and advance its product candidates through clinical trials. Positive clinical trial results could lead to a significant increase in stock price, while negative results could lead to a further decline.

PBLA Stock Forecast 2024

In 2024, we expect PBLA’s stock price to stabilize, with a minimum target of $1 USD and a maximum target of $3 USD. The company’s success in securing additional funding and advancing its product candidates through clinical trials will continue to be a key driver of its stock price. Positive clinical trial results could lead to increased investor confidence and a higher stock price, while negative results could lead to a decline.

PBLA Stock Forecast 20252030

Looking further ahead, we expect PBLA’s stock price to gradually increase as the company advances its product candidates through clinical trials and seeks regulatory approval. By 2030, we expect the company’s stock price to reach a minimum target of $5 USD and a maximum target of $10 USD. However, this forecast is subject to change based on the company’s financial performance and the outcome of its clinical trials.

PBLA Stock Forecast 2030-2050

In the long term, we expect PBLA’s stock price to continue to increase as the company brings its product candidates to market and generates revenue. By 2050, we expect the company’s stock price to reach a minimum target of $20 USD and a maximum target of $50 USD. However, this forecast is highly speculative and subject to change based on a variety of factors, including the company’s financial performance, competition, and market conditions.

Long-Term PBLA Stock Forecast

YearForecasted Minimum Forecasted Maximum

Analyst Recommendations

Daily Low / High

Telegram Channel👉 Click Here 🎯
Facebook Page👉 Click Here 🎯

PBLA Stock Price in 2014?

– According to Google historical data, the price of PBLA on 19 DEC 2014 was $6600.

What is the Current PBLA Stock Price?

– As of 19 December 2023, the current stock price of PBLA is $1.01 Check out today’s current stock price.

PBLA Stock Forecast 2023?

– Based on our analysis, the maximum PBLA Stock Forecast in 2023 could be $2.50.

To stay updated with the latest information related to the stock market and receive live stock market updates, follow Stockdhan and stay connected with us. Check out Today’s Share Market Open or Closed.

Google NewsFacebook

I would like to remind you that I am not authorized by the SEC to provide any financial advice or recommendations. As you know, Stock Forecast is not an exact science, That’s why I am conducting in-depth research and using different AI tools to predict share prices. My purpose is only educational, and I am using AI to see what the future of the stock might look like.

Disclaimer– These Stock Price Targets for “PBLA Stock Forecast” are only provided for informational purposes only. It does not constitute a recommendation to buy, sell, or hold PBLA stock. Investors should conduct their own research and analysis and consult with financial experts before making any investment decisions—


In 2015, I Started Working as a Blogger Now I am a Versatile Professional With Experience in Blogging and Content Writing. I entered the stock market as a beginner in 2017. I was passionate about the stock market and learned something new every day. I Conduct Thorough Research and Produce High-Quality Content for Our Readers. Every Piece of Content Is Based on My Extensive Expertise and In-Depth Research.